Abstract

Objective: This retrospective, two-center study aimed to provide solid clinical evidence to support the viral attenuation theory after passages of SARS-CoV-2 during the early stages of the pandemic. Methods: Clinical characteristics and outcomes of 150 COVID-19 patients hospitalized in Wenzhou, China between January and April 2020 were compared. These patients had similar demographic characteristics. Infections of 77 patients who visited Wuhan within 14 days before symptom onset were categorized as imported cases and that of the remaining 73 patients who had no recent travel history were categorized as locally transmitted cases. Results: COVID-19 cases in Wenzhou appeared to be mostly mild at the early stages of the pandemic. There were no differences in clinical manifestations, laboratory testing results, and radiographic presentation between imported and locally transmitted cases in Wenzhou, except that a higher proportion of lymphopenia was found in the imported case group. Assessment of infection severity showed that severe conditions were observed in 10.7% of the patients, with the imported case group having a significantly higher rate (15.6%) than the locally transmitted case group (5.5%, x2 = 4.016, p = 0.045). Conclusion: Although, the clinical manifestations of locally acquired infections were indistinguishable from those imported from Wuhan, they were less likely to develop into severe medical conditions, suggesting the possibility of virulence attenuation after viral passages during the early stages of the pandemic.

Highlights

  • AND BACKGROUNDThe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan (Hubei Province, China) in December 2019 as a novel member of the Coronavirus group and causes the highly infectious coronavirus disease 2019 (COVID-19) [1 - 3]

  • The gene sequence of SARS-CoV-2 is highly similar to that of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) [8], with both viruses harboring genes encoding spike glycoproteins that bind to Angiotensin Converting Enzyme 2 (ACE2) on the surface of Type II alveolar epithelial cells and/or hepatocytes, causing severe damage to the respiratory system and the liver [9, 10]

  • The first COVID-19 case in Wenzhou was diagnosed on January 16, 2020 and the patient was immediately admitted to the Wenzhou Central Hospital

Read more

Summary

Introduction

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan (Hubei Province, China) in December 2019 as a novel member of the Coronavirus group and causes the highly infectious coronavirus disease 2019 (COVID-19) [1 - 3]. Wenzhou was among the areas most severely affected by COVID-19 outside the Hubei province. The epidemiological features and transmission dynamics of COVID-19 beyond Wuhan and the Hubei province have been well described [13]. Human-to-human transmission of SARS-CoV-2 is well established, affecting individuals of all ages, including children and infants, with an incubation period of 3-14 days after infection [14, 15]. Detection and contact tracing are extremely important strategies for the successful management of the COVID-19 pandemic [17]. New diagnostic assays based on nanomaterial technologies, such as the plasmonic meta sensor technology that targets SARSCoV-2 spike proteins, are currently under development for rapid and precise screening of SARS-CoV-2 virus carriers [18, 19]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call